Recombinant Lactococcus lactis NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT-29 cells

Microbial Cell Factories

Volumn 15, Issue 1, 2016, Pages

  Zhang, Bo ^a   Li, Angdi ^a   Zuo, Fanglei ^a   Yu, Rui ^a   Zeng, Zhu ^a   Ma, Huiqin ^a   Chen, Shangwu ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

Delivery vector; Functional protein; KiSS1; Lactococcus lactis

Indexed keywords

GELATINASE B; KISSPEPTIN; MESSENGER RNA; NISIN; G PROTEIN COUPLED RECEPTOR; KISS1R PROTEIN, HUMAN; RECOMBINANT PROTEIN;

APOPTOSIS; ARTICLE; BACTERIAL STRAIN; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; LACTOCOCCUS LACTIS; MTT ASSAY; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; WOUND HEALING; BIOSYNTHESIS; CELL MOTION; DOWN REGULATION; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HT-29 CELL LINE; ISOLATION AND PURIFICATION; METABOLISM; PLASMID; SECRETION (PROCESS);

APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; HT29 CELLS; HUMANS; KISSPEPTINS; LACTOCOCCUS LACTIS; MATRIX METALLOPROTEINASE 9; PLASMIDS; RECEPTORS, G-PROTEIN-COUPLED; RECOMBINANT PROTEINS;

EID: 84975482405     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/s12934-016-0506-7     Document Type: Article

References (49)

1. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today. 2006;11:905-10.
2. Araújo F, Fonte P, Santos HA, Sarmento B. Oral delivery of glucagon-like peptide-1 and analogs: alternatives for diabetes control? J Diabetes Sci Technol. 2012;6:1486-97.
3. Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today. 2003;8:259-66.
4. Win KY, Feng S-S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26:2713-22.
5. Sani I, Abdulhamid A, Bello F. Oral protein-drug delivery systems suitable for systemic circulation. Int J Modern Biol Med. 2014;5:5-16.
6. Wyszyńska A, Kobierecka P, Bardowski J, Jagusztyn-Krynicka EK. Lactic acid bacteria-20 years exploring their potential as live vectors for mucosal vaccination. Appl Microbiol Biotechnol. 2015;99:2967-77.
7. Varma NRS, Toosa H, Foo HL, Alitheen NBM, Nor Shamsudin M, Arbab AS, Yusoff K, Abdul Rahim R. Display of the viral epitopes on Lactococcus lactis: a model for food grade vaccine against EV71. Biotechnol Res Int. 2013;2013:431315.
8. Mierau I, Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol. 2005;68:705-17.
9. Desmond C, Fitzgerald G, Stanton C, Ross R. Improved stress tolerance of GroESL-overproducing Lactococcus lactis and probiotic Lactobacillus paracasei NFBC 338. Appl Environ Microbiol. 2004;70:5929-36.
10. Benbouziane B, Ribelles P, Aubry C, Martin R, Kharrat P, Riazi A, Langella P, Bermudez-Humaran LG. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J Biotechnol. 2013;168:120-9.
11. Liang X, Zhang L, Zhong J, Huan L. Secretory expression of a heterologous nattokinase in Lactococcus lactis. Appl Microbiol Biotechnol. 2007;75:95-101.
12. Shigemori S, Yonekura S, Sato T, Nakanishi M, Otani H, Shimosato T. Expression of a biologically active GFP-αS1-casein fusion protein in Lactococcus lactis. Curr Microbiol. 2012;64:569-75.
13. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:754-9.
14. Cano-Garrido O, Seras-Franzoso J, Garcia-Fruitós E. Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. Microb Cell Fact. 2015;14:137.
15. Ng DT, Sarkar CA. Nisin-inducible secretion of a biologically active single-chain insulin analog by Lactococcus lactis NZ9000. Biotechnol Bioeng. 2011;108:1987-96.
16. Hunter KW, Crawford N, Alsarraj J. Mechanisms of metastasis. Breast Cancer Res. 2008;10:S2.
17. Lee J-H, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996;88:1731-7.
18. Shirasaki F, Takata M, Hatta N, Takehara K. Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16. 3-q23. Cancer Res. 2001;61:7422-5.
19. Ringel MD, Hardy E, Bernet VJ, Burch HB, Schuppert F, Burman KD, Saji M. Metastin receptor is overexpressed in papillary thyroid cancer and activates MAP kinase in thyroid cancer cells. J Clin Endocrinol Metab. 2002;87:2399.
20. Sanchez-Carbayo M, Capodieci P, Cordon-Cardo C. Tumor suppressor role of KiSS-1 in bladder cancer: loss of KiSS-1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol. 2003;162:609-17.
21. Dhar DK, Naora H, Kubota H, Maruyama R, Yoshimura H, Tonomoto Y, Tachibana M, Ono T, Otani H, Nagasue N. Downregulation of KiSS-1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma. Int J Cancer. 2004;111:868-72.
22. Ikeguchi M, Yamaguchi K-I, Kaibara N. Clinical Significance of the Loss of KiSS-1 and orphan G-protein-coupled receptor (hOT7T175) gene expression in esophageal squamous cell carcinoma. Clin Cancer Res. 2004;10:1379-83.
23. Moya P, Esteban S, Fernandez-Suarez A, Maestro M, Morente M, Sánchez-Carbayo M. KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer. Tumor Biol. 2013;34:471-9.
24. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 2001;411:613-7.
25. Cho SG, Li D, Stafford LJ, Luo J, Rodriguez-Villanueva M, Wang Y, Liu M. KiSS1 suppresses TNFα-induced breast cancer cell invasion via an inhibition of RhoA-Mediated NF-ΚB activation. J Cell Biochem. 2009;107:1139-49.
26. Stathaki M, Armakolas A, Dimakakos A, Kaklamanis L, Vlachos I, Konstantoulakis MM, Zografos G, Koutsilieris M. Kisspeptin effect on endothelial monocyte activating polypeptide II (EMAP-II)-associated lymphocyte cell death and metastases in colorectal cancer patients. Mol Med. 2014;20:80.
27. Matsui H, Takatsu Y, Kumano S, Matsumoto H, Ohtaki T. Peripheral administration of metastin induces marked gonadotropin release and ovulation in the rat. Biochem Biophys Res Commun. 2004;320:383-8.
28. Lee J-H, Welch DR. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res. 1997;57:2384-7.
29. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-74.
30. Ji K, Ye L, Ruge F, Hargest R, Mason MD, Jiang WG. Implication of metastasis suppressor gene, Kiss-1 and its receptor Kiss-1R in colorectal cancer. BMC Cancer. 2014;14:1.
31. Nash KT, Welch DR. The KISS1 metastasis suppressor: mechanistic insights and clinical utility. Front Biosci. 2006;11:647.
32. Gorbach SL. Lactic acid bacteria and human health. Ann Med. 1990;22:37-41.
33. Hirayama K, Rafter J. The role of lactic acid bacteria in colon cancer prevention: mechanistic considerations. Antonie Van Leeuwenhoek. 1999;76:391-4.
34. Ruas-Madiedo P, Hugenholtz J, Zoon P. An overview of the functionality of exopolysaccharides produced by lactic acid bacteria. Int Dairy J. 2002;12:163-71.
35. Looijesteijn PJ, Trapet L, de Vries E, Abee T, Hugenholtz J. Physiological function of exopolysaccharides produced by Lactococcus lactis. Int J Food Microbiol. 2001;64:71-80.
36. Olbrich T, Ziegler E, Türk G, Schubert A, Emons G, Gründker C. Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: evidence for a dose-window effect. Gynecol Oncol. 2010;119:571-8.
37. Schmidt E, Haase M, Ziegler E, Emons G, Gründker C. Kisspeptin-10 inhibits stromal-derived factor 1-induced invasion of human endometrial cancer cells. Int J Gynecol Cancer. 2014;24:210-7.
38. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta. 2012;1825:29-36.
39. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52-67.
40. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2011;41:271-90.
41. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997;277:225-8.
42. Zhang Y, Tang Y, Li Z, Pan F, Huang K, Xu G. KiSS1 inhibits growth and invasion of osteosarcoma cells through inhibition of the MAPK pathway. Eur J Histochem. 2013;57:30.
43. Zheng S, Chang Y, Hodges KB, Sun Y, Ma X, Xue Y, Williamson SR, Lopez-Beltran A, Montironi R, Cheng L. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res. 2010;30:713-8.
44. Lee KH, Kim J-R. Kiss-1 suppresses MMP-9 expression by activating p38 MAP kinase in human stomach cancer. Oncol Res Featur Preclin Clin Cancer Ther. 2009;18:107-16.
45. Yan C, Wang H, Boyd DD. KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-ΚB binding to the promoter as a consequence of IΚBα-induced block of p65/p50 nuclear translocation. J Biol Chem. 2001;276:1164-72.
46. Kuipers OP, de Ruyter PG, Kleerebezem M, de Vos WM. Quorum sensing-controlled gene expression in lactic acid bacteria. J Biotechnol. 1998;64:15-21.
47. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. New York: Cold spring harbor laboratory press; 1989.
48. van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Meth Mol Biol. 2011;731:237-45.
49. Chen H-J, Jiang Y-L, Lin C-M, Tsai S-C, Peng S-F, Fushiya S, Hour M-J, Yang J-S. Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells. Int J Oncol. 2013;43:141-50.